Hong Kong-listed ophthalmic service provider Chaoju Eye Care Holdings Limited released its latest Next Day Disclosure Return (26 May 2026), confirming no change in total issued ordinary shares while outlining a series of on-market share repurchases executed in April-May 2026.

Key Share Capital Metrics • Issued shares (excluding treasury shares) remained at 705.18 million as of both 21 May and 26 May 2026. • All repurchased shares—currently 682,000 in total—have not yet been cancelled; once cancelled, the outstanding share count will decrease by about 0.10%.

Repurchase Activity: 2 April–26 May 2026 • Thirteen on-market buy-backs totalled 682,000 shares, equal to approximately 0.10% of issued shares. • Aggregate consideration reached roughly HK$1.92 million, implying a volume-weighted average price of about HK$2.82 per share. • Daily repurchase prices ranged between HK$2.62 and HK$3.02.

Latest Transaction (26 May 2026) • Quantity: 60,000 shares for cancellation • Price range: HK$2.62–HK$2.68 • Total outlay: HK$0.16 million

Repurchase Mandate Status • Shareholders approved a new mandate on 12 May 2026, authorising buy-backs of up to 70.52 million shares. • Since grant, 300,000 shares (0.04% of issued shares on mandate date) have been repurchased under the new authority. • In line with Hong Kong Stock Exchange rules, Chaoju Eye Care is subject to a 30-day moratorium on new share issues or treasury share sales until 25 June 2026.

Compliance Statement The board confirmed that all repurchases were executed on the Exchange, fully authorised and conducted in compliance with Main Board Rule 10.06 and related regulatory requirements.